Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study.
covid-19 lockdown
glycaemic control
psychological health
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
03
03
2021
received:
03
02
2021
accepted:
19
03
2021
pubmed:
26
3
2021
medline:
23
6
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
To assess the effect of the coronavirus disease 2019 (COVID-19) lockdown on glycaemic control in subjects with type 2 diabetes (T2D). In this observational, multicentre, retrospective study conducted in the Lazio region, Italy, we compared the differences in the HbA1c levels of 141 subjects with T2D exposed to lockdown with 123 matched controls with T2D who attended the study centres 1 year before. Basal data were collected from 9 December to 9 March and follow-up data from 3 June to 10 July in 2020 for the lockdown group, and during the same timeframes in 2019 for the control groups. Changes in HbA1c (ΔHbA1c) and body mass index (ΔBMI) during lockdown were compared among patients with different psychological well-being, as evaluated by tertiles of the Psychological General Well-Being Index (PGWBS). No difference in ΔHbA1c was found between the lockdown and control groups (lockdown group -0.1% [-0.5%-0.3%] vs. control group -0.1% [-0.4%-0.2%]; p = .482). Also, no difference was found in ΔBMI (p = .316) or ΔGlucose (p = .538). In the lockdown group, subjects with worse PGWBS showed a worsening of HbA1c (p = .041 for the trend among PGWBS tertiles) and BMI (p = .022). The COVID-19 lockdown did not significantly impact glycaemic control in people with T2D. People with poor psychological well-being may experience a worsening a glycaemic control because of restrictions resulting from lockdown. These findings may aid healthcare providers in diabetes management once the second wave of COVID-19 has ended.
Identifiants
pubmed: 33764666
doi: 10.1111/dom.14380
pmc: PMC8251001
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1624-1630Subventions
Organisme : No funding supported this study.
Informations de copyright
© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Diabetes Care. 2020 Aug;43(8):e88-e89
pubmed: 32540921
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Diabetes Care. 2020 Aug;43(8):e86-e87
pubmed: 32503838
Obes Med. 2020 Sep;19:100290
pubmed: 32844132
Diabetol Metab Syndr. 2020 Aug 31;12:76
pubmed: 32879637
Prog Cardiovasc Dis. 2021 Jan-Feb;64:108-110
pubmed: 32277997
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Diabetes Obes Metab. 2021 Jul;23(7):1624-1630
pubmed: 33764666
Acta Diabetol. 2021 Apr;58(4):431-436
pubmed: 33219884
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1815-1819
pubmed: 32956926
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1571-1574
pubmed: 32858474
Diabetes Care. 2021 Mar;44(3):839-843
pubmed: 33361146
Int J Diabetes Dev Ctries. 2020 Oct 21;:1-6
pubmed: 33106739
Diabetes Res Clin Pract. 2020 Nov;169:108454
pubmed: 32971157
Diabetes Metab Res Rev. 2016 Feb;32(2):169-75
pubmed: 26484614
Cardiovasc Diabetol. 2020 Oct 1;19(1):164
pubmed: 33004045
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1963-1966
pubmed: 33059299
Health Qual Life Outcomes. 2006 Nov 14;4:88
pubmed: 17105655